CALT
Calliditas Therapeutics AB
$22.8
Earnings Summary
Revenue | $0Mn |
Net Profits | $-61.33Mn |
Net Profit Margins | -Inf% |
Highlights
Calliditas Therapeutics AB’s revenue fell -100% since last year same period to $0Mn in the Q2 2020. On a quarterly growth basis, Calliditas Therapeutics AB has generated -100% fall in its revenue since last 3-months.
Calliditas Therapeutics AB’s net profit fell -173.74% since last year same period to $-61.33Mn in the Q2 2020. On a quarterly growth basis, Calliditas Therapeutics AB has generated 3.75% jump in its net profits since last 3-months.
Calliditas Therapeutics AB’s net profit margin fell -Inf% since last year same period to -Inf% in the Q2 2020. On a quarterly growth basis, Calliditas Therapeutics AB has generated -Inf% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Calliditas Therapeutics AB post its latest quarter earnings
EPS Estimate Current Quarter | 0.27 |
EPS Estimate Current Year | 0.27 |
Highlights
Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current quarter stand at 0.27 - a 178.77% jump from last quarter’s estimates.
Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current year stand at 0.27.
Key Ratios
Key ratios of the Calliditas Therapeutics AB post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Calliditas Therapeutics AB’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Calliditas Therapeutics AB has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2020-06-30 | -0.4 | -0.31 | 22.5% |
2020-03-31 | 0 | -0.34 | -Inf% |
2020-09-30 | -0.26 | -0.62 | -138.46% |
2020-12-31 | -0.45 | -0.79 | -75.56% |
Company Information
Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Organisation | Calliditas Therapeutics AB |
Headquarters | Kungsbron 1, D5, Stockholm, Sweden, 111 22 |
Employees | 102 |
Industry | Health Technology |
CEO | Renee J. Aguiar-Lucander |
